Minimal residual disease (MRD) analysis of BCR-ABL positive acute lymphocytic leukemia (ALL) patients during STI571 kinase inhibitor therapy.

被引：0
|
作者：
Scheuring, UJ
Wassmann, B
Pfeiffer, H
Capdeville, R
Petershofen, E
Gschaidmeier, H
Hoelzer, D
Ottmann, OG
机构：
[1] Univ Frankfurt, Dept Hematol, D-6000 Frankfurt, Germany
[2] Novartis Pharma AG, Basel, Switzerland
[3] DRK Blood Bank, Frankfurt, Germany
来源：
BLOOD | 2000年 / 96卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
2002
引用
收藏
页码：465A / 465A
页数：1
相关论文
共 50 条
  • [1] Prognostic relevance of minimal residual disease (MRD) analysis in BCR-ABL positive acute lymphoblastic leukemia (ALL) patients during Gleevec (STI571) therapy.
    Scheuring, UJ
    Pfeifer, H
    Brueck, P
    Wassmann, B
    Atta, J
    Gschaidmeier, H
    Petershofen, E
    Hoelzer, DF
    Ottmann, OG
    BLOOD, 2001, 98 (11) : 762A - 763A
  • [2] STI571:: Bcr-Abl kinase inhibition as the basis of therapy for CML
    Mauro, MJ
    Druker, BJ
    LEUKEMIA, 2001, 15 (03) : 488 - 488
  • [3] Monitoring minimal residual disease by BCR-ABL Western and quantitative competitive RT PCR in Philadelphia chromosome (Ph)-positive chronic myelogenous leukemia (CML) on STI571 therapy.
    Quackenbush, RC
    Talpaz, M
    Guo, JQ
    Arlinghaus, RB
    Resta, D
    Capdeville, R
    Rios, MB
    Giles, FJ
    Kantarjian, HM
    BLOOD, 2000, 96 (11) : 736A - 736A
  • [4] Novel targeted therapies for Bcr-Abl positive acute leukemias: beyond STI571
    Nimmanapalli, R
    Bhalla, K
    ONCOGENE, 2002, 21 (56) : 8584 - 8590
  • [5] Detection of resistance to STI571 in patients with BCR-ABL positive acute leukemia and chronic myeloid leukemia (CML) blast crisis.
    Mahon, FX
    Belloc, F
    Cholet, C
    Cony-Makhoul, P
    Guilhot, F
    Melo, JV
    Berthaud, P
    Reiffers, J
    BLOOD, 2000, 96 (11) : 471A - 471A
  • [6] Effect of a selective Abl tyrosine kinase inhibitor, STI571, on in vitro growth of BCR-ABL-positive acute lymphoblastic leukemia cells
    Kawaguchi, Y
    Jinnai, I
    Nagai, K
    Yagasaki, F
    Yakata, Y
    Matsuo, T
    Kuriyama, K
    Tomonaga, M
    LEUKEMIA, 2001, 15 (04) : 590 - 594
  • [7] Effect of a selective Abl tyrosine kinase inhibitor, STI571, on in vitro growth of BCR-ABL-positive acute lymphoblastic leukemia cells
    Y Kawaguchi
    I Jinnai
    K Nagai
    F Yagasaki
    Y Yakata
    T Matsuo
    K Kuriyama
    M Tomonaga
    Leukemia, 2001, 15 : 590 - 594
  • [8] Ph+ acute lymphoblastic leukemia resistant to the tyrosine kinase inhibitor STI571 has a unique BCR-ABL gene mutation
    Hofmann, WK
    Jones, LC
    Lemp, NA
    de Vos, S
    Gschaidmeier, H
    Hoelzer, D
    Ottmann, OG
    Koeffler, HP
    BLOOD, 2002, 99 (05) : 1860 - 1862
  • [9] Minimal residual disease monitoring by quantitative real time-PCR during treatment with STI571 for bcr/abl-positive acute lymphoblastic leukemia.
    Martinelli, G
    Piccaluga, PP
    Malagola, M
    Rondoni, M
    Soverini, S
    Amabile, M
    Pane, F
    Bianchini, M
    Ottaviani, E
    Giannini, B
    Vigna, E
    Bosi, C
    Gaitani, S
    Paolini, S
    Russo, D
    Visani, G
    Fiacchini, M
    Baccarani, M
    BLOOD, 2003, 102 (11) : 245B - 246B
  • [10] Minimal residual disease (MRD) monitoring in chronic myelogenous leukemia (CML) patients treated with STI571 (Glivec®)
    Roche-Lestienne, C
    Grardel-Duflos, N
    Cornu-Soenen, V
    Laï, JL
    Roumier, C
    Berthaud, P
    Cosson, A
    Facon, T
    Preudhomme, C
    LEUKEMIA, 2001, 15 (12) : 2023 - 2023
12345